Kevin Conroy

Genomic Health

Is Exact Sciences Stock a Buy? | 11/19/2019

Exact Sciences just completed its multibillion-dollar acquisition of Genomic Health, setting the stage for the company’s future. (TMFHaen) Nov 19, 2019 at 11:28AM This month, Exact Sciences ( NASDAQ:EXAS ) finalized its purchase of Genomic … test. On its third-quarter conference call, Chairman and CEO Kevin Conroy spelled out its goal for Cologuard to “capture at least 40% of the U.S. colorectal screening market,” a significant increase from the current …

Follow Kevin Conroy:    

BizTimes Milwaukee: Exact Sciences Corp. completes $2.8 billion acquisition | 11/12/2019

Genomic Health , the company announced. Exact Sciences produces Cologuard, a noninvasive, at-home screening test that detects the presence of colon cancer in stool samples. Genomic Health develops Oncotype IQ, a portfolio of genomic tests and services that check for various cancers, including breast and prostate. “Today marks a pivotal step toward building the world’s leading advanced cancer diagnostics company,” said Kevin Conroy, chairman and CEO of Exact Sciences. “We’re …

Exact Sciences completes acquisition of Genomic Health for $2.8bn | 11/11/2019

Molecular diagnostics firm Exact Sciences has closed its approximately $2.8bn acquisition of genomic diagnostics maker Genomic Health. In July, Exact Sciences signed a definitive agreement to acquire genomic diagnostics maker Genomic Health in a cash-and-stock deal. Exact Sciences chairman and CEO Kevin Conroy said: “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along …

Pfizer

Is Exact Sciences Stock a Buy? | 11/19/2019

Kevin Conroy spelled out its goal for Cologuard to “capture at least 40% of the U.S. colorectal screening market,” a significant increase from the current 5% penetration. Don’t forget that Pfizer ( NYSE:PFE ) , in partnership with Exact, continues to pound the pavement to bring awareness to physicians about colorectal cancer and Cologuard. What’s motivating Pfizer? More diagnosed patients mean a greater number of potential patients for its colorectal cancer treatments …

Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation – Company Announcement - FT.com | Financial Times | 11/8/2019

… to current guidelines v . “A growing number of patients around the world are considered high risk for developing HCC,” said Kevin Conroy , chairman and CEO of Exact Sciences . “A more sensitive and convenient blood-based … effectively utilize strategic partnerships, such as our Promotion Agreement with Pfizer, Inc. , and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations …

Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company – Company Announcement - FT.com | Financial Times | 11/8/2019

… Genomic Health , Inc. (NASDAQ: GHDX). “Today marks a pivotal step toward building the world’s leading advanced cancer diagnostics company,” said Kevin Conroy , chairman and CEO of Exact Sciences . “We’re excited to bring together some of … utilize strategic partnerships, such as through our Promotion Agreement with Pfizer, Inc. , and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations …

Oncotype

Is Exact Sciences Stock a Buy? | 11/19/2019

… marketer for future tests, whether discovered in-house or developed in partnership with other companies. The company’s products Cologuard and Oncotype DX together seek to gain traction in what Exact claims is a $20 billion … test. On its third-quarter conference call, Chairman and CEO Kevin Conroy spelled out its goal for Cologuard to “capture at least 40% of the U.S. colorectal screening market,” a significant increase from the current …

BizTimes Milwaukee: Exact Sciences Corp. completes $2.8 billion acquisition | 11/12/2019

Oncotype IQ, a portfolio of genomic tests and services that check for various cancers, including breast and prostate. “Today marks a pivotal step toward building the world’s leading advanced cancer diagnostics company,” said Kevin Conroy, chairman and CEO of Exact Sciences. “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along their cancer journey.” As a …

Exact Sciences completes acquisition of Genomic Health for $2.8bn | 11/11/2019

… definitive agreement to acquire genomic diagnostics maker Genomic Health in a cash-and-stock deal. Exact Sciences chairman and CEO Kevin Conroy said: “We’re excited to bring together some of the greatest minds in cancer … for colorectal cancer will now be supported by Genomic Health’s Oncotype DX gene expression tests to facilitate therapy decisions for colorectal, breast and prostate cancers. As part of the deal, Exact Sciences will have a …

Cancer Diagnostics

Is Exact Sciences Stock a Buy? | 11/19/2019

… This month, Exact Sciences ( NASDAQ:EXAS ) finalized its purchase of Genomic Health, creating a formidable player in the realm of cancer diagnostics. Exact shelled out approximately $1.06 billion in cash and issued roughly 17.4 million … test. On its third-quarter conference call, Chairman and CEO Kevin Conroy spelled out its goal for Cologuard to “capture at least 40% of the U.S. colorectal screening market,” a significant increase from the current …

BizTimes Milwaukee: Exact Sciences Corp. completes $2.8 billion acquisition | 11/12/2019

by Tech Council Nov 12, 2019 NEWSROOM , Tech Council News Madison-based cancer diagnostics company Exact Sciences Corp. completed its $2.8 billion cash-and-stock deal with Redwood City, California-based Genomic Health , the company … toward building the world’s leading advanced cancer diagnostics company,” said Kevin Conroy, chairman and CEO of Exact Sciences. “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver …

Exact Sciences completes acquisition of Genomic Health for $2.8bn | 11/11/2019

Molecular diagnostics firm Exact Sciences has closed its approximately $2.8bn acquisition of genomic diagnostics maker Genomic Health. In July, Exact Sciences signed a definitive agreement to acquire genomic diagnostics maker Genomic Health in a cash-and-stock deal. Exact Sciences chairman and CEO Kevin Conroy said: “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along …

Cancer Diagnostics

Is Exact Sciences Stock a Buy? | 11/19/2019

… This month, Exact Sciences ( NASDAQ:EXAS ) finalized its purchase of Genomic Health, creating a formidable player in the realm of cancer diagnostics. Exact shelled out approximately $1.06 billion in cash and issued roughly 17.4 million … test. On its third-quarter conference call, Chairman and CEO Kevin Conroy spelled out its goal for Cologuard to “capture at least 40% of the U.S. colorectal screening market,” a significant increase from the current …

BizTimes Milwaukee: Exact Sciences Corp. completes $2.8 billion acquisition | 11/12/2019

by Tech Council Nov 12, 2019 NEWSROOM , Tech Council News Madison-based cancer diagnostics company Exact Sciences Corp. completed its $2.8 billion cash-and-stock deal with Redwood City, California-based Genomic Health , the company … toward building the world’s leading advanced cancer diagnostics company,” said Kevin Conroy, chairman and CEO of Exact Sciences. “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver …

Exact Sciences completes acquisition of Genomic Health for $2.8bn | 11/11/2019

Molecular diagnostics firm Exact Sciences has closed its approximately $2.8bn acquisition of genomic diagnostics maker Genomic Health. In July, Exact Sciences signed a definitive agreement to acquire genomic diagnostics maker Genomic Health in a cash-and-stock deal. Exact Sciences chairman and CEO Kevin Conroy said: “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along …

Food and Drug Administration

Is Exact Sciences Stock a Buy? | 11/19/2019

Food and Drug Administration (FDA) expanded the approved Cologuard patient population to include average-risk individuals ages 45 and older, whereas ages 50 and above had been the prior limit. That translates into 19 million more people who could receive the Cologuard test. On its third-quarter conference call, Chairman and CEO Kevin Conroy spelled out its goal for Cologuard to “capture at least 40% of the U.S. colorectal screening …

Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation – Company Announcement - FT.com | Financial Times | 11/8/2019

… for patient care and ongoing research. Exact Sciences’ HCC test has also been granted Breakthrough Device designation by the U.S. Food and Drug Administration . The agency’s Breakthrough Devices program expedites development, assessment, and review processes … the world are considered high risk for developing HCC,” said Kevin Conroy , chairman and CEO of Exact Sciences . “A more sensitive and convenient blood-based test could help catch the disease earlier, which may lead …

Diagnostic Tests

WisBusiness: Exact Sciences liver cancer test granted breakthrough device designation | 11/13/2019

Kevin Conroy says recently published study results show an improvement over other diagnostic tests. A release from the company shows more than 42,000 Americans and 780,000 people around the world are diagnosed with liver cancer each year, with HCC accounting for about 90 percent of cases. “There is a significant, worldwide unmet need for a blood-based, early detection diagnostic test for liver cancer in persons with elevated risk for …

Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation – Company Announcement - FT.com | Financial Times | 11/8/2019

… to current guidelines v . “A growing number of patients around the world are considered high risk for developing HCC,” said Kevin Conroy , chairman and CEO of Exact Sciences . “A more sensitive and convenient blood-based … Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Fueled by the success of Cologuard and Oncotype …

Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company – Company Announcement - FT.com | Financial Times | 11/8/2019

… Genomic Health , Inc. (NASDAQ: GHDX). “Today marks a pivotal step toward building the world’s leading advanced cancer diagnostics company,” said Kevin Conroy , chairman and CEO of Exact Sciences . “We’re excited to bring together some of … Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Fueled by the success of Cologuard and Oncotype …